A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis

Trial Profile

A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Bedaquiline (Primary) ; Pretomanid (Primary) ; Clofazimine; Linezolid; Moxifloxacin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TB-PRACTECAL
  • Most Recent Events

    • 16 Jan 2017 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
    • 16 Jan 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
    • 16 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top